Emerging treatments

Tumor necrosis factor (TNF)-alpha inhibitors

Mild elevations of TNF have been identified in the serum of ReA patients compared with controls.[72] Observational data suggest clinical benefit among ReA patients receiving TNF-alpha inhibitors; prospective randomised controlled trials are required.[73][74][75][76][77] There is some evidence to suggest TNF-alpha inhibitors do not re-activate the infective trigger in patients with ReA.[59]

Antibiotics

Several prospective randomised controlled trials have indicated that antibiotic therapy may be of benefit in patients with post-chlamydial ReA.[78][46][79][80] However, a systematic review and meta-analysis found that antibiotic treatment had no significant effect on remission of ReA triggered by chlamydial infection.[81] Heterogeneity in trial results was reported and may have been attributable to differences in study design.[81] There is no data to suggest that long-term antibiotics have any therapeutic effect in the treatment of post-enteric infection. Further high quality prospective RCTs are needed to confirm the role of antibiotic therapy in the management of post-chlamydial ReA.

Use of this content is subject to our disclaimer